PREVENT-HF: A Phase IIB Study of Carvedilol in Survivors of Childhood Cancer at Risk for Heart Failure

Full Title

ALTE1621: Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial (CIRB)

Purpose

Survivors of childhood cancers who were treated with anthracycline drugs (such as doxorubicin) may have an increased risk of heart failure. Carvedilol is a drug commonly used to treat heart failure (inability of the heart to pump efficiently) and high blood pressure and to prevent heart failure in survivors of heart attacks. In this study, researchers want to see if carvedilol is effective for reducing the risk of heart failure in survivors of childhood cancers who received anthracycline drugs.

Participants in this study will be randomly assigned to receive carvedilol or a placebo (inactive drug) for up to two years. Carvedilol and the placebo are both pills that are taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Participants must have received anthracycline therapy as treatment for a childhood cancer (cancer diagnosed before age 21) and must have completed cancer treatment two or more years before entering the study.
  • Participants may not be receiving treatment for cardiomyopathy or heart failure. Blood pressure-lowering medication is only permitted if it is a calcium channel blocker or diuretic drug.

For more information about this study and to inquire about eligibility, please contact Dr. Anthony Yu at 212-639-7932.

Protocol

16-1206

Phase

II

Investigator

Co-Investigators

Locations